'Networking INnovation actors in the medical device sector' 8.6% of GDP in Europe is spent on health, of which 6.4% is for medical technology. Although this expenditure delivers an exceptional return on investment, there is a need for continual innovation. Increasing patient treatment and operating costs mean that the commercial prospe...

Commercialisation of first-class research and the development of the European Biotech Healthcare sector are problematic especially in terms of unmet financial needs and poor cooperation between sector actors. The lack of early-stage risk capital severely hampers the formation of innovative start-up companies: Europe's start-ups need new forms...